Why Immunomedics Shares Crashed 13.5% Today
After Goldman Sachs (NYSE:GS) cut its rating from a “buy” to a “sell” following reports the Food and Drug Administration (FDA) may have concerns over its manufacturing process, Immunomedics (NASDAQ:IMMU) shares tumbled 13.5% at 3:45 pm EST on Friday. In early 2019, the company was issued an FDA complete response letter rejecting an …
News story posted on 2020-04-03T23:45:00.0000000Z